Directori

ANNA VERT COMPANY

Translational Research on Cardiovascular Respiratory Diseases

Firma

ANNA VERT-COMPANY

Position

Tècnic/a Investigador/a

Technicians

Projectes

Translational Research on Cardiovascular Respiratory Diseases

VASCULAR AND ENDOTHELIAL IMPLICATIONS OF COVID-19: INVESTIGATING THE MECHANISM OF LONG-TERM EFFECT (VENICE).

Codi oficial: GLD24/00100 Start date:01/01/2025 Data fi: 01/12/2026 Investigador/a principal: OLGA TURA CEIDE Organisme finançador: GILEAD SCIENCES, S.L.U

Publicacions

Translational Research on Cardiovascular Respiratory Diseases

Vert A, Castro J, Ribó M, Vilanova M, Benito A

Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance

ONCOTARGETS AND THERAPY, 2018, 11, 221-237 dx.doi.org/10.2147/OTT.S154378

Translational Research on Cardiovascular Respiratory Diseases

Vert A, Castro J, Ribó M, Benito A, Vilanova M

Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase.

Oncotarget, 2017, 8, 11692-11707 dx.doi.org/10.18632/oncotarget.14302

Formulari de contacte

Board of trustees

Center of

Directori

ANNA VERT COMPANY

Projectes

Publicacions

Transcriptional profiling of NCI/ADR-RES cells unveils a complex network of signaling pathways and molecular mechanisms of drug resistance

Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase.

Formulari de contacte

About IDIBGI!